Physician profile
Aaron Spector
NPI 1619077716
$100,356.56
in general payments reported to CMS, 2019-2025
26 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19K · 2022: $21K · 2023: $24K · 2024: $21K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $4,725 · Consulting Fee: $4,238 · Travel and Lodging: $2,498 · Education: $1.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,733.15 |
| Food and Beverage | $4,725.32 |
| Consulting Fee | $4,238.00 |
| Travel and Lodging | $2,498.20 |
| Education | $1.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $53,778.54 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $33,143.71 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $5,695.89 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $3,658.42 | 2021-2023 | Aristada, Lybalvi, Vivitrol |
| Sunovion Pharmaceuticals INC. | $706.88 | 2021-2022 | |
| Bausch Health US, LLC | $669.88 | 2021-2025 | Aplenzin, Wellbutrin |
| Teva Pharmaceuticals USA, INC. | $535.58 | 2021-2023 | Uzedy, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $436.97 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $315.85 | 2021-2024 | Trintellix |
| Axsome Therapeutics, INC. | $236.98 | 2022-2025 | Sunosi, Auvelity |
| Lundbeck LLC | $152.95 | 2021-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $142.00 | 2021-2025 | Fanapt |
| Corium, LLC | $137.19 | 2022-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $99.28 | 2021-2025 | Spravato, Invega, Invega Sustenna |
| Adlon Therapeutics L.P. | $85.29 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $81.37 | 2022-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $71.15 | 2024 | |
| Eisai INC. | $66.68 | 2021 | |
| Neurocrine Biosciences, INC. | $60.69 | 2022-2024 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $58.40 | 2022-2023 | Quviviq |
| Almatica Pharma LLC | $56.58 | 2022 | |
| Noven Therapeutics, LLC | $52.59 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $41.11 | 2021-2022 | |
| Tris Pharma INC | $30.96 | 2023-2024 | Dyanavel Xr |
| Avanir Pharmaceuticals, INC. | $24.64 | 2021 | |
| Neos Therapeutics, LP | $16.98 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Spector listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.